MX2017012694A - Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon. - Google Patents

Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon.

Info

Publication number
MX2017012694A
MX2017012694A MX2017012694A MX2017012694A MX2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A
Authority
MX
Mexico
Prior art keywords
methods
nonalcoholic
glucagon receptor
fatty liver
liver disease
Prior art date
Application number
MX2017012694A
Other languages
English (en)
Inventor
Yan Hai
SHI Jim
Oh Jeong
Original Assignee
Remb Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remb Biotherapeutics Inc filed Critical Remb Biotherapeutics Inc
Publication of MX2017012694A publication Critical patent/MX2017012694A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a métodos para tratar o prevenir la obesidad y/o las enfermedades de hígado graso no alcohólicas (NAFLDs) y/o esteatohepatitis no alcohólica (NASH) utilizando un agente bloqueador del receptor de glucagón. En diversas modalidades, la presente descripción se refiere a métodos para tratar o prevenir NAFLD/NASH utilizando proteínas de unión a antígenos y antagonistas, e.g., anticuerpos totalmente humanos, que se unen específicamente y antagonizan la función del receptor de glucagón humano.
MX2017012694A 2015-04-02 2016-03-31 Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon. MX2017012694A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562142257P 2015-04-02 2015-04-02
PCT/US2016/025336 WO2016161154A1 (en) 2015-04-02 2016-03-31 Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies

Publications (1)

Publication Number Publication Date
MX2017012694A true MX2017012694A (es) 2018-03-07

Family

ID=57006366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012694A MX2017012694A (es) 2015-04-02 2016-03-31 Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon.

Country Status (9)

Country Link
US (2) US10752693B2 (es)
EP (1) EP3277830A4 (es)
JP (1) JP6861641B2 (es)
KR (1) KR20170138456A (es)
CN (1) CN107614695B (es)
AU (1) AU2016242935B2 (es)
CA (1) CA2980765A1 (es)
MX (1) MX2017012694A (es)
WO (1) WO2016161154A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129555A1 (en) * 2017-01-09 2018-07-12 Temple University - Of The Commonwealth System Of Higher Education Methods and compositions for treatment of non-alcoholic steatohepatitis
MX2019008722A (es) 2017-01-27 2019-10-02 Ngm Biopharmaceuticals Inc Proteínas de unión al receptor de glucagón y métodos para usarlas.
KR102686854B1 (ko) * 2017-08-09 2024-07-18 사노피 지방간 질환 및 지방간염의 치료에서의 glp-1/글루카곤 수용체 작용제
EA202092122A1 (ru) * 2018-03-08 2020-12-03 Фейнз Терапьютикс, Инк. Антитела против tip-1 и их применения
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
CN111068042B (zh) * 2018-10-18 2023-10-13 中山大学 一种多肽化合物在制备治疗非酒精性肝病、特发性肺间质纤维化和动脉硬化药物中的应用
EP3876924A4 (en) * 2018-11-06 2022-08-10 Georgetown University TREATMENT OF NALCOHOLIC STEATOHEPATITIS WITH CCK INHIBITORS
EP3901173A4 (en) 2018-12-21 2022-11-23 Jiangsu Hengrui Medicine Co., Ltd. BISPECIFIC PROTEIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
CL2009001424A1 (es) * 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
EP2758533B1 (en) * 2011-09-20 2018-04-11 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
JP2016520058A (ja) * 2013-05-07 2016-07-11 ライナット ニューロサイエンス コーポレイション 抗グルカゴン受容体抗体およびその使用方法
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

Also Published As

Publication number Publication date
AU2016242935A1 (en) 2017-11-09
KR20170138456A (ko) 2017-12-15
AU2016242935B2 (en) 2020-10-01
US20200339697A1 (en) 2020-10-29
JP6861641B2 (ja) 2021-04-21
EP3277830A4 (en) 2018-11-21
CN107614695A (zh) 2018-01-19
CA2980765A1 (en) 2016-10-06
US10752693B2 (en) 2020-08-25
CN107614695B (zh) 2022-01-25
US20180079820A1 (en) 2018-03-22
EP3277830A1 (en) 2018-02-07
JP2018512417A (ja) 2018-05-17
WO2016161154A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MX2017012694A (es) Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PH12017502359B1 (en) Glucagon and glp-1 co-agonist compounds
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2017006301A (es) Conjugados de anticuerpo- farmaco.
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2016016210A (es) Metodos para el tratamiento de diabetes tipo 1 utilizando anticuerpos antagonistas del receptor de glucagon.
MX2017011480A (es) Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo.
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
WO2014144616A3 (en) Anti-alpha v beta 5 antibodies and uses thereof